Table 2.
Breakdown of adverse drug reactions.
n = 54 | |
---|---|
Number of events (%) | |
A. Assessment of the causality of adverse drug reactions | |
Certain | 6 (11.1) |
Probable/ likely | 12 (22.2) |
Possible | 36 (66.7) |
B. Classification of adverse drug reactions | |
Gastrointestinal disorders | 23 (42.6) |
Skin and subcutaneous tissue disorders | 9 (16.7) |
Investigations | 6 (11.1) |
Infections and infestations | 4 (7.4) |
General disorders and administration site conditions | 3 (5.6) |
Nervous system disorders | 3 (5.6) |
Metabolism and nutrition disorders | 2 (3.7) |
Blood and lymphatic system disorders | 1 (1.9) |
Immune system disorders | 1 (1.9) |
Psychiatric disorders | 1 (1.9) |
Respiratory, Thoracic and mediastinal disorders | 1 (1.9) |
C. Severity of adverse drug reactions* | |
Grade 1 | 31 (57.4) |
Grade 2 | 13 (24.1) |
Grade 3 | 10 (18.5) |
Grade 4 | 0 (0) |
Grade 5 | 0 (0) |
D. Classification of suspected drugs related to adverse drug reactions | |
Antiinfectives for systemic use | 30 (55.6) |
Respiratory system | 10 (18.5) |
Antineoplastic and immunomodulating agents | 8 (14.8) |
Nervous system | 4 (7.4) |
Alimentary tract and metabolism | 1 (1.9) |
Blood and blood forming organs | 1 (1.9) |
Each adverse drug reaction was counted, even when there is more than one adverse drug reaction per patient.
*Grade refers to the severity of the adverse events according to Common Terminology Criteria for Adverse Events v5.0. Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age appropriate instrumental activities of daily life. Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily life. Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death related to AE.